Q4 25 EPS
$0.16
BEAT +132.90%
Est. $0.07
Q4 25 Revenue
$719.4M
BEAT +12.10%
Est. $641.7M
vs S&P Since Q4 25
-5.3%
TRAILING MARKET
DOC -0.8% vs S&P +4.5%
Full Year 2025 Results
FY 25 EPS
$0.10
BEAT +1,100.00%
Est. $-0.01
FY 25 Revenue
$2.82B
BEAT +2.83%
Est. $2.74B
Market Reaction
Did DOC Beat Earnings? Q4 2025 Results
Healthpeak Properties delivered a standout fourth quarter, posting earnings per share of $0.16 against a consensus estimate of $0.07, a beat of 132.90%, while revenue of $719.40 million cleared expectations of $641.73 million by 12.10% and rose 3.1% … Read more Healthpeak Properties delivered a standout fourth quarter, posting earnings per share of $0.16 against a consensus estimate of $0.07, a beat of 132.90%, while revenue of $719.40 million cleared expectations of $641.73 million by 12.10% and rose 3.1% year-over-year. The primary engine behind the outperformance was aggressive capital deployment, headlined by the $600.00 million acquisition of the Gateway Crossing life science campus in South San Francisco and roughly $675.00 million in senior housing investments assembled during the quarter. Perhaps the boldest strategic move was the announced formation of Janus Living, Inc., a dedicated senior housing REIT that Healthpeak plans to take public in the first half of 2026, a structure management believes will unlock value that diversified REITs have historically struggled to capture in public markets, a theme resonating broadly across the healthcare real estate sector. Looking ahead, Healthpeak guided 2026 Nareit FFO per share to $1.70 to $1.74, with same-store NOI growth of negative 1% to positive 1%, as life science fundamentals show early signs of stabilization after a prolonged downturn.
Key Takeaways
- • Total Merger-Combined Same-Store Cash (Adjusted) NOI growth of +3.9% year-over-year in Q4
- • Life Plan same-store NOI growth of +16.7% year-over-year in Q4
- • Outpatient Medical same-store NOI growth of +4.1% year-over-year in Q4
- • Record non-refundable entry fee cash collections of $153 million in 2025
- • Outpatient Medical renewal cash releasing spreads of +4.4% in Q4
- • Lab renewal lease executions averaged 84-month term
- • Q4 new and renewal lease executions totaled 2.1 million square feet
DOC YoY Financials
Q4 2025 vs Q4 2024, source: SEC Filings
DOC Revenue by Segment
With YoY comparisons, source: SEC Filings
DOC Earnings Trends
DOC vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
DOC EPS Trend
Earnings per share: estimate vs actual
DOC Revenue Trend
Quarterly revenue: estimate vs actual
DOC Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 | — | — | — | — | — |
| Q4 25 BEAT FY | $0.07 | $0.16 | +132.90% | $719.4M | +12.10% |
| FY Full Year | $-0.01 | $0.10 | +1,100.00% | $2.82B | +2.83% |
| Q3 25 MISS | $0.06 | $-0.17 | -383.33% | $705.9M | +3.65% |
| Q2 25 MISS | $0.06 | $0.05 | -11.82% | $694.3M | +0.11% |
| Q1 25 BEAT | $0.05 | $0.06 | +33.33% | $702.9M | +1.98% |